Description: IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
Home Page: www.iqvia.com
2400 Ellis Road
Durham,
NC
27703
United States
Phone:
919 998 2000
Officers
| Name | Title |
|---|---|
| Mr. Ari Bousbib | CEO & Chairman |
| Mr. Ronald E. Bruehlman | Executive VP & CFO |
| Mr. Eric M. Sherbet J.D. | Executive VP, General Counsel & Secretary |
| Mr. W. Richard Staub III | President of Research & Development Solutions |
| Ms. Keriann Cherofsky | Senior VP, Corporate Controller & Chief Accounting Officer |
| Mr. Jim Berkshire | Executive Vice President of Global Technology & Operations |
| Dr. Jeffrey A. Spaeder M.D. | Senior VP, Global Chief Medical & Scientific Officer |
| Kerri Joseph | SVP of Investment Relation & Treasury |
| Ms. Trudy Stein | Chief Human Resources Officer & Executive VP |
| Dr. Cynthia L. Verst | President of Design & Delivery Innovation |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 16.6113 |
|---|---|
| Trailing PE: | 26.6783 |
| Price-to-Book MRQ: | 5.2822 |
| Price-to-Sales TTM: | 2.2701 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 88000 |